English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
A ‘Miracle’: Spinraza Gives Boy, Now 5, a Chance to Grow Up
It’s now been more than four years since Spinraza (nusinersen) was first approved by the U.S. Food and Drug Administration, and presymptomatic children with spinal muscular atrophy (SMA) who received the therapy as part of the Phase 2 NURTURE trial are growing up fast and, by all accounts, showing good progress.
Jase Yoder, 5, is one of those children. He was featured as part of “The Gene” documentary on PBS last year. In the segment, Jase, who has SMA type 1, can be seen jumping on a trampoline. Sitting up, walking, and jumping were all milestones Jase would have likely not achieved if it weren’t for Spinraza infusions. In fact, children with SMA type 1 typically don’t make it past the age of 2.
BookmarkRelated Content
-
The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is a rare,...
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
Every Day You Don’t Lose, You Are WinningJennifer Summers, 35, is an optimistic, ...
-
Nonrespiratory Complications of Nusinersen-Treated Spinal Muscular Atrophy Type 1 PatientsBackground: Emergence of new treatments ...
-
Real-World Safety of Nusinersen in Japan: Results From an Interim Analysis of a Post-Marketing Surveillance and Safe...Purpose: Nusinersen is the first disease...
-
Spine Surgery Effective in SMA Type 1 Children, But Not Without RisksSurgery to correct kyphoscoliosis — a ...
-
Quality of Life Assessment in Adult Spinal Muscular Atrophy Patients Treated With NusinersenObjective: To retrospectively evaluate q...
Powered by
In partnership with
